RT Journal Article
T1 Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
A1 Cuypers, Lize
A1 Perez, Ana Belen
A1 Chueca, Natalia
A1 Aldamiz-Echevarria, Teresa
A1 Alados, Juan Carlos
A1 Martinez-Sapiña, Ana Maria
A1 Merino, Dolores
A1 Pineda, Juan Antonio
A1 Tellez, Francisco
A1 Espinosa, Nuria
A1 Salmeron, Javier
A1 Rivero-Juarez, Antonio
A1 Vivancos, Maria Jesus
A1 Hontañon, Víctor
A1 Vandamme, Anne-Mieke
A1 Garcia, Federico
AB Despite high response rates associated to hepatitis C virus (HCV) treatment, no protective immunity is acquired, allowing for reinfection and continued infectiousness. Distinguishing between relapse and reinfection is crucial for patient counselling and to choose the most appropriate retreatment. Here, refined phylogenetic analysis using multiple genes served to assess genotype and reinfection for 53 patients for whom the virus was sampled before start of therapy and at time of sustained virological response evaluation at week 12. At baseline, genotypes were determined as HCV1a (41.5%), HCV1b (24.5%), HCV4 (18.9%) and HCV3a (15.1%), while six cases revealed to be discordantly assigned by phylogeny and commercial assays. Overall, 60.4% was co-infected with HIV. The large majority was classified as people who inject drugs (78.6%), often co-infected with HIV. Transmission was sexual in seven cases, of which five in HIV-positive men-who-have-sex-with-men. Overall, relapse was defined for 44 patients, while no conclusion was drawn for four patients. Five patients were reinfected with a different HCV strain, of which three with a different genotype, showing that phylogeny is needed not only to determine the genotype, but also to distinguish between relapse and intra-subtype reinfection. Of note, phylogenies are more reliable when longer fragments of the viral genome are being sequenced.
PB Public Library of Science
YR 2018
FD 2018-07-11
LK http://hdl.handle.net/10668/12754
UL http://hdl.handle.net/10668/12754
LA en
NO Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, et al. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis. PLoS One. 2018 Jul 25;13(7):e0201268
DS RISalud
RD Mar 14, 2025